期刊档案 · ONCOLOGY
International Cancer Conference Journal
ISSN 2192-3183 · 4 issues per year
International Cancer Conference Journal 中科院 医学 4区(2025 年升级版),影响因子 0.4(官网公布),混合开放获取,APC 约 4,090 美元,近 24 个月 101 篇文章投稿到接收中位 100 天,2025 年发文 97 篇,ESCI 收录。
研究范围
研究范围与定位
International Cancer Conference Journal 属中科院医学大类(2025 升级版4区)。按 OpenAlex 近年发文统计,该刊主要发表 Sarcoma Diagnosis and Treatment、Ovarian cancer diagnosis and treatment、Cancer Immunotherapy and Biomarkers 等主题的论文,这 3 个主题约占 18.9%,主导子领域为 Pulmonary and Respiratory Medicine、Oncology。(根据 OpenAlex 主题统计与中科院分区数据生成)
This peer-reviewed online-only journal publishes original case reports on all types of cancer, together with literature reviews on related or similar cases. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on cancer cases involving molecular analysis and concerning e.g. gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Deciding how to conduct the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop targeted medicine solutions in the future. International Cancer Conference Journal is the official quarterly publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports, together with literature reviews on all types of cancer - In particular, welcomes cancer cases involving molecular analysis - The Official Publication of the Japan Society of Clinical Oncology (JSCO)
摘自期刊官网 Aims & Scope
研究方向(LetPub):ONCOLOGY
主编 Hidetoshi Eguchi出版商官网
编委会国家分布:未见中国大陆编委;主要国家 日本 22(共 22 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Sarcoma Diagnosis and TreatmentMedicine7.1%
- Ovarian cancer diagnosis and treatmentMedicine6.4%
- Cancer Immunotherapy and BiomarkersMedicine5.5%
- Renal cell carcinoma treatmentMedicine5.4%
- Gastric Cancer Management and OutcomesMedicine5.4%
- Neuroendocrine Tumor Research AdvancesMedicine5.2%
- Cancer Diagnosis and TreatmentMedicine4.5%
- Lung Cancer Research StudiesMedicine4.3%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊:否综述期刊:否
《新锐期刊分区表》( 2026年3月发布)医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)未收录
该期刊未被此版本分区表收录。
数据库收录
ESCILetPub
国际期刊预警名单:各版本均未列入LetPub
期刊官网自述收录
Embase出版商官网
其他:Google Scholar、EBSCO、ProQuest、Dimensions、CNKI、Baidu、Naver、OCLC、Portico、CLOCKSS、Semantic Scholar
期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子(出版商公布) 2025
- 0.4出版商官网 ·
- 五年影响因子(出版商公布) 2025
- 0.5出版商官网 ·
- h-index
- 15OpenAlex ·
- i10-index
- 49OpenAlex ·
- 两年平均被引
- 0.88OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 12.24%LetPub ·
发文规模
- 年文章数
- 94LetPub ·
- 年下载量(出版商公布) 2025
- 117,400出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 913 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 79 | 77 | 15 |
| 2025 | 97 | 97 | 79 |
| 2024 | 97 | 96 | 147 |
| 2023 | 51 | 51 | 89 |
| 2022 | 64 | 64 | 179 |
| 2021 | 68 | 68 | 235 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
100 天投稿到接收中位数 · P25–P75 69 天 – 132 天
- 接收到上线
- 中位数 18 天(101 篇)
- 投稿到上线
- 中位数 123 天
- 样本
- 101 篇有投稿与接收日期的文章(窗口内共 192 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 投稿到首次决定
- 7 天出版商官网 ·
- 评审方式
- 单盲同行评审、双盲同行评审出版商官网
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊,作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 4,090 / EUR 3,090 / GBP 2,690 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取;按订阅方式发表通常不收费。
其他费用与减免(作者指南)
- 版面费
- 无版面费
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
投稿准备要点7 项,摘自作者指南
- 关键词
- ≥ 3 个
- 正文篇幅
- ≤ 3,000 词
- 参考文献格式
- 顺序编码制(按引用顺序编号)
- 首次投稿格式
- 允许不按期刊格式排版(free format)
- 推荐审稿人
- 可选
- 投稿信(Cover letter)
- 必须提供
- 不接收
- Review articles
接收的文章类型10 种,含篇幅限制
- brief communicationManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …未说明篇幅
- case reportManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …正文 ≤ 3,000 词
- case reportsManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …未说明篇幅
- editorialManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …未说明篇幅
- letterManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …未说明篇幅
- letters to the editorManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …正文 ≤ 500 词
- literature reviewManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …未说明篇幅
- review articleManuscripts may be submitted to the International Journal of Cancer Conference (ICCJ) in the form of case reports (usually accompanied by a literature review), …未说明篇幅
- review articlesExternally submitted review articles will not be considered for publication. Only review articles solicited by the society or the editorial board will be eligib…未说明篇幅
- video articlesVideo articles are brief communications describing a novel surgical technique or a standardized procedure for oncology cases with an accompanying abstract and m…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、试验注册 / 报告规范
- AI 使用 Generative AI Images
作者应查阅Springer关于生成式AI图像的政策,并确保其工作符合其中所述的原则。 模型中文摘要
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
原文 ↗出版商官网 ·- 作者资格 Authorship principles
期刊和出版商假定所有作者同意稿件内容并明确同意提交,且已获得所在机构负责部门的同意;出版商不规定何种贡献构成作者身份,建议作者遵循适用的作者身份指南。 模型中文摘要
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
原文 ↗出版商官网 ·- 利益冲突 Competing Interests
作者应披露与所投稿件直接或间接相关的利益,包括开始工作(开展研究和准备投稿)前3年内的利益;3年之外的利益如可能被合理认为影响所投稿件也必须披露。 模型中文摘要
Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclo…
原文 ↗出版商官网 ·- 数据可用性 Data availability statement:
所有原创研究必须包含数据可用性声明;伦理批准、知情同意和作者贡献声明等其他声明也可包含在内。 模型中文摘要
All original research must include a data availability statement. See “Research Data Policy and Data Availability Statements” below. Other statements such as ethics approval, informed consent, and authors’ contribution statements may also be included. References Formatting must conform to the styles described in the “References” section below.Figure caption should be included in the text file of t…
原文 ↗出版商官网 ·- 出版伦理
视频中不应包含可能识别患者身份的信息(如姓名、首字母或医院编号),除非该信息对科学目的必不可少且患者(或其父母或监护人)已就发表给予书面知情同意。 模型中文摘要
Information that may identify patients, including names, initials, or hospital numbers should not be included in videos unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication.
原文 ↗出版商官网 ·- 许可与版权 Copyright
Open Choice文章无需转让版权,版权仍归作者所有;选择开放获取即表示作者同意在知识共享许可下发表文章。 模型中文摘要
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide.
原文 ↗出版商官网 ·- 开放获取 Open access publishing
欲了解在《International Cancer Conference Journal》开放获取发表(包括费用、资助和许可信息),请访问该期刊的开放获取出版页面。 模型中文摘要
To find out more about publishing your work Open Access in International Cancer Conference Journal, including information on fees, funding and licences, visit our Open access publishing page. Back to top
原文 ↗出版商官网 ·- 同行评审
该期刊采用单盲同行评审,审稿人知晓作者的姓名和所属机构,但提供给作者的审稿报告是匿名的。 模型中文摘要
This journal follows a single-blind reviewing procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to the authors are anonymous.
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical Trial Registration
世界卫生组织将临床试验定义为前瞻性地将人类受试者或人群分配到一个或多个健康相关干预措施以评估健康结局影响的研究。 模型中文摘要
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版周期
- 4 issues per year
- ISSN
- 2192-3183
- 学会 / 主办单位
- Japan Society of Clinical Oncology
- 官网最新一期
- Volume 15, Issue 3(2026 年 7 月)
常见问题
关于 International Cancer Conference Journal 的常见问题
International Cancer Conference Journal 是中科院几区期刊?
2025 年升级版分区表中,International Cancer Conference Journal 为医学 4区,小类 肿瘤学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
International Cancer Conference Journal 的影响因子是多少?
期刊官网公布的影响因子为 0.4(2025 年度),属期刊自述数据,LetPub 暂无该刊的影响因子记录,h-index 为 15。
International Cancer Conference Journal 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)101 篇已发表文章登记的日期,投稿到接收的中位数为 100 天(四分位 69–132 天)。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
International Cancer Conference Journal 的投稿格式要求是什么?
据期刊作者指南:关键词:≥ 3 个;正文篇幅:≤ 3,000 词;参考文献格式:顺序编码制(按引用顺序编号);首次投稿格式:允许不按期刊格式排版(free format);推荐审稿人:可选;投稿信:必须提供。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。
International Cancer Conference Journal 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 22 位编委中,没有中国大陆学者;人数最多的国家是 日本(22 位)。统计按编委会页面列出的机构国家计,仅供参考。
International Cancer Conference Journal 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,International Cancer Conference Journal 被 ESCI 收录。期刊官网自述还被 Embase 收录,该清单未与各数据库逐一核对。
International Cancer Conference Journal 是开放获取期刊吗?版面费多少?
International Cancer Conference Journal 为混合开放获取。选择开放获取发表时APC 约 4,090 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。